What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Affiliations

Editorial

Ikuo Sekine. J Thorac Dis. 2017 May.

. 2017 May;9(5):E447-E450.

doi: 10.21037/jtd.2017.04.43.

¹ Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: Honoraria—Chugai Pharmaceutical Co., Novartis Pharma, and Pfizer.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. Soria JC, et al. Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Lancet. 2017. PMID: 28126333 Clinical Trial.

1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006. 10.1001/jama.2014.3741 - DOI - PMC - PubMed
1. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-81. 10.1158/1078-0432.CCR-13-0318 - DOI - PMC - PubMed
1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15. 10.1038/modpathol.2009.2 - DOI - PubMed
1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9. 10.1016/S1470-2045(12)70344-3 - DOI - PMC - PubMed
1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. 10.1056/NEJMoa1006448 - DOI - PMC - PubMed